Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAdministrative/Operational PolicyProvidence Prior Auth Part B Drugs Policy Update |…
    Ask Trek AI about this page
    CurrentProvidence Health PlanPolicy N/A

    Providence Medicare Advantage Plans 2026 Prior Authorization Criteria for Part B Drugs

    Customize your policy alerts

    Sign up for all Providence Health Plan policy alerts

    Know when Providence Health Plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document lists Providence Medicare Advantage Plans' prior authorization requirements for selected Medicare Part B drugs (infused or injected) and provides contact information for providers and members about obtaining prior authorization. It affects Providence Medicare Advantage Plan members and their prescribing providers.

    Policy Summary
    PayerProvidence Health Plan
    PolicyProvidence Medicare Advantage Plans 2026 Prior Authorization Criteria for Part B Drugs
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateMay 1, 2026
    Next Review DateN/A
    Key ActionProviders must obtain prior authorization for certain Medicare Part B injectable or infusible medications before the plan will agree to cover them.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    hundreds

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Part B drugs listed for prior authorization
    20+Document segment entries
    ~120Listed drugs/procedure codes visible
    7d/wkCustomer service hours

    Medicare Part B Drugs Requiring Prior Authorization

    List of Part B drugs requiring prior authorization

    The document enumerates Medicare Part B drugs (injected or infused) that require prior authorization and, where available, provides a link to the policy criteria and an effective-date flag.

    ALL of the following

    • Part B drugs subject to prior authorization include (examples):

      • Q2055 — Abecma (Idecabtagene vicleucel) (Click to view policy criteria).
      • J9264 — Abraxane (Paclitaxel protein-bound particles) (Click to view policy criteria).
      • J3262 — Actemra (Tocilizumab) (Click to view policy criteria).
      • J0791 — Adakveo (Crizanlizumab-tmca) (Click to view policy criteria).
      • J9042 — Adcetris (Brentuximab vedotin) (Click to view policy criteria).
      • J9029 — Adstiladrin (Nadofaragene firadenovec) (Click to view policy criteria).
      • J7171 — Adzynma (ADAMTS13, recombinant-krhn) (Click to view policy criteria).
      • J9302 — Arzerra (Ofatumumab) (Click to view policy criteria).
      • J1554 — Asceniv (Immune globulin) (Click to view policy criteria).
      • J9118 — Asparlas (Calaspargase pegol-mknl) (Click to view policy criteria).
      • Q2058 — Aucatzyl (Obecabtagene autoleucel) (Click to view policy criteria).
      • Q5161 — Aukelso/Bosaya (denosumab-kyqq) (Click to view policy criteria; example effective date 4/1/2026).
      • J9035 — Avastin (Bevacizumab) (Click to view policy criteria).
      • J3145 — Aveed (Testosterone undecanoate) (Click to view policy criteria).
      • J3590/C9399 — Avlayah (Tividenofusp alfa-eknm) (Click to view policy criteria; example effective date 5/1/2026).
      • Q5121 — Avsola (Infliximab-axxq) (Click to view policy criteria).
      • A4253 — Diabetic DME Test Strips (Document link: Click to view).
      • J9172 — Docivyx (Docetaxel) (Click to view policy criteria).
      • J7351 — Durysta (Bimatoprost intracameral implant) (Click to view policy criteria).
      • J0586 — Dysport (AbobotulinumtoxinA) (Click to view policy criteria).
      • J9063 — Elahere (Mirvetuximab soravtansine-gynx) (Click to view policy criteria).
      • J1743 — Elaprase (Idursulfase) (Click to view policy criteria).
      • J3060 — Elelyso (Taliglucerase alfa) (Click to view policy criteria).
    • This list is illustrative — the full roster contains many additional HCPCS/J-codes and mapped drug names; for each listed code a document link labeled 'Click to view' indicates where the detailed prior authorization criteria can be reviewed.

    Listed Part B drugs and links to prior authorization criteria

    Roster of additional Part B drugs with HCPCS/J-codes and document links to their prior authorization criteria; many entries include an 'if after 1/1/2026' effective-date flag.

    ALL of the following

    • Representative listings include:

      • J9061 / Q5119 — Rybrevant (Amivantamab-vmjw) / Rybrevant Faspro (amivantamab-hyaluronidase-) (Click to view; example effective date 5/1/2026).
      • J9021 — Rylaze (Asparaginase, recombinant) (Click to view policy criteria).
      • J3402 — Ryoncil (Remestemcel-l-rknd) (Click to view policy criteria).
      • J2998 — Ryplazim (Plasminogen, human-tvmh) (Click to view policy criteria).

    Procedure and HCPCS/J Codes

    Sample J/Q codes from drug listHCPCSCovered
    Q2055Abecma (Idecabtagene vicleucel).
    J9264Abraxane (Paclitaxel protein-bound particles).
    J3262Actemra (Tocilizumab).
    (source note)mixed
    sourceEntries shown include clickable policy criteria links and optional 'if after 1/1/2026' effective-date fields.
    Additional codesHCPCSCovered
    Q5130Fylnetra (Pegfilgrastim-pbbk).
    J9210Gamifant (Emapalumab-lzsg).
    (source note)mixed
    sourceEntries include 'click to view' links and optional 'if after 1/1/2026' effective-date fields.
    sample Part B drug codesHCPCS
    Q5130Fylnetra (Pegfilgrastim-pbbk).
    S0132Fylnetra / Fyremadel (Ganirelix acetate) references.
    J1460GamaSTAN S/D (Immune globulin).
    J1569Gammagard Liquid (Immune globulin).
    J1566Gammagard S-D (Immune globulin).
    J1561Gammaked / Gamunex-C (Immune globulin).
    J1557Gammaplex (Immune globulin).
    J0223Givlaari (Givosiran).
    J0257Glassia (Alpha 1 proteinase inhibitor (human)).
    J9301Gazyva (Obinutuzumab).
    (source note)mixed
    sourceEach entry includes a 'Click to view' link for policy criteria; some list an 'if after 1/1/2026' effective date.
    sample HCPCS/J-codes and mapped drug names from chunks 36-49HCPCS
    J9061Rybrevant (Amivantamab-vmjw) / Rybrevant Faspro.
    J9021Rylaze (Asparaginase, recombinant).
    J3402Ryoncil (Remestemcel-l-rknd).
    J2998Ryplazim (Plasminogen, human-tvmh).
    J9333Rystiggo (Rozanolixizumab-noli).
    J2353Sandostatin LAR Depot (Octreotide acetate, microspheres).
    J9227Sarclisa (Isatuximab-irf) / Saphnelo (Anifrolumab-fnia).
    J3590/C9399Skysona (Elivaldogene autotemcel) / Soliris (Eculizumab).
    J2326Spinraza (Nusinersen).
    J2323Tysabri (Natalizumab).
    1–10 of 13
    1/2
    (source note)mixed
    effective_date_noteMany entries include an 'if after 1/1/2026' field (often blank or with a later date).
    effective_date_note
    NoteMany listed Part B drug entries include an 'if after 1/1/2026' effective-date field; some entries are blank while others show a later effective date (e.g., 5/1/2026, 2/1/2026).
    Typical contentField appears alongside each procedure code and medication name to indicate when the policy criteria become effective if after 1/1/2026.
    Examples from documentJ9061 and J9999/C9399 show 'if after 1/1/2026' = 5/1/2026; J1553 shows 'if after 1/1/2026' = 2/1/2026.
    Blank valuesMany entries list the field but leave it blank when no later effective date applies.

    What Providers Must Do

    Prior Authorization

    Prior authorization required for selected Medicare Part B drugs

    Providence Medicare Advantage Plans requires prior authorization for certain Medicare Part B medications (injected or infused) before the plan will agree to cover them; lack of prior authorization may result in non-coverage.

    Documentation Required

    How to request prior authorization / contact information

    For questions or to request prior authorization, call Providence Medicare Advantage Plans at 503-574-8000 or 1-800-603-2340. TTY users should call 711; customer service hours are seven days a week, 8 a.m. to 8 p.m. PT (seasonal weekend hours noted in header).

    Prior Authorization

    Prior authorization drug/code roster with links and effective-date flags

    Terminology and Field Definitions

    Prior authorization
    DefinitionPrior authorization is approval the plan requires in advance for certain medical services, including administration of certain medications (injected or infused) before the plan will agree to cover the drug.
    PurposeTo ensure appropriate use of certain drugs and guide utilization of specialty injected or infused medications.
    ConsequenceIf prior authorization is not obtained, the drug might not be covered by the plan.
    Click to view
    Label text'Click to view' is the document link text used in the drug listing to open the specific prior authorization policy criteria for each listed procedure code and medication.
    UsageDisplayed next to each HCPCS/J-code and medication name to indicate an accessible policy criteria document for that entry.
    Policy Summary
    PayerProvidence Health Plan
    PolicyProvidence Medicare Advantage Plans 2026 Prior Authorization Criteria for Part B Drugs
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateMay 1, 2026
    Next Review DateN/A
    Key ActionProviders must obtain prior authorization for certain Medicare Part B injectable or infusible medications before the plan will agree to cover them.
    SourceLink
    On This Page
    Medicare Part B Drugs Requiring Prior AuthorizationProcedure and HCPCS/J CodesWhat Providers Must DoTerminology and Field Definitions
    J9333 — Rystiggo (Rozanolixizumab-noli) (Click to view policy criteria).
  1. J0870 — Rytelo (Imetelstat) (Click to view policy criteria).
  2. J9361 — Ryzneuta (Efbemalenograstim alfa-vuxw) (Click to view policy criteria).
  3. J2353 — Sandostatin LAR Depot (Octreotide acetate, microspheres) (Click to view policy criteria).
  4. J9202 — Zoladex (Goserelin acetate implant) (Click to view policy criteria).
  5. J3399 — Zolgensma (Onasemnogene abeparvovec-xioi) (Click to view policy criteria).
  6. J9282 — Zusduri (Mitomycin) (Click to view policy criteria).
  7. J9359 — Zynlonta (Loncastuximab tesirine-lpyl) (Click to view policy criteria).
  8. J3393 — Zynteglo (Betibeglogene autotemcel) (Click to view policy criteria).
  9. J9345 — Zynyz (Retifanlimab-dlwr) (Click to view policy criteria).
  10. For the complete roster and to review the specific prior authorization requirements for a given HCPCS/J-code, use the document link labeled 'Click to view' associated with that code.
  11. The document lists multiple HCPCS/J (and other procedure) codes paired with medication names and provides a document link labeled 'Click to view' for each entry; many entries also include an 'if after 1/1/2026' effective-date field that may indicate when criteria apply.

    • Entries show: Code, Medication Name, (click to view the policy criteria) and (if after 1/1/2026) fields.
    • Many listed entries include a clickable 'Click to view' policy criteria link.
    Prior Authorization

    Part B drug prior authorization listing with document links

    The Parts B drug listing enumerates specific HCPCS/CPT/procedure codes paired with medication names (for example Q5130 = Fylnetra; J9061 = Rybrevant; J9021 = Rylaze) and shows a 'Click to view' document link for each code; several entries include an 'if after 1/1/2026' value (some are 5/1/2026 or blank).

    • Sample entries from the listing: Q5130 — Fylnetra (Click to view).
    • J9061 — Rybrevant (Click to view) (if after 1/1/2026 = 5/1/2026).
    • J9021 — Rylaze (Click to view).
    AppearanceAppears repeatedly in the listing (e.g., Q5130, J1569, J9061, J9228 etc.) as the Document Link column entry.
    if after 1/1/2026
    If after 1/1/2026Field used to indicate a later effective date for the policy criteria that applies only if the criteria become effective after 1/1/2026; examples include 5/1/2026 (J9061, J9999/C9399) and 2/1/2026 (J1553).
    Common stateFrequently present but often blank when no later effective date applies.
    PlacementShown as the third column (Effective Date) alongside each Procedure Code(s) and Document Link entries.
    Procedure Code(s) fields
    Column 1Medication Name — lists the drug name paired with the procedure code (e.g., J9228 = Yervoy (Ipilimumab)).
    Column 2Document Link — 'Click to view' is used to access the specific prior authorization policy criteria for the medication.
    Column 3Effective Date — 'if after 1/1/2026' field showing the effective date when criteria apply after 1/1/2026 (may be blank or contain a later date).